Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging

Kristina Buder12*, Constantin Lapa3, Michael C Kreissl34, Andreas Schirbel3, Ken Herrmann3, Alexander Schnack5, Eva-Bettina Bröcker1, Matthias Goebeler1, Andreas K Buck3 and Jürgen C Becker16

  • * Corresponding author: Kristina Buder

  • † Equal contributors

Author Affiliations

1 Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Josef-Schneider-Strasse 2, 97080 Würzburg, Germany

2 Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Josef-Schneider-Strasse 6, 97080 Würzburg, Germany

3 Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacher Strasse 6, 97080 Würzburg, Germany

4 Department of Nuclear Medicine, Central Hospital of Augsburg, Stenglinstr.2, 86156 Augsburg, Germany

5 Department of Radiology, University Hospital Würzburg, Oberdürrbacher Strasse 6, 97080 Würzburg, Germany

6 Department of General Dermatology, Medical University Graz, Auenbrugger Platz 1, 8036 Graz, Austria

For all author emails, please log on.

BMC Cancer 2014, 14:268  doi:10.1186/1471-2407-14-268

Published: 17 April 2014



Merkel cell carcinoma (MCC) is a rare cutaneous neoplasm with increasing incidence, aggressive behavior and poor prognosis. Somatostatin receptors (SSTR) are expressed in MCC and represent a potential target for both imaging and treatment.


To non-invasively assess SSTR expression in MCC using PET and the radiotracers [68Ga]DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) or -octreotate (DOTATATE) as surrogate for tumor burden. In 24 patients with histologically proven MCC SSTR-PET was performed and compared to results of computed tomography (CT).


SSTR-PET detected primary and metastatic MCC lesions. On a patient-based analysis, sensitivity of SSTR-PET was 73% for nodal metastases, 100% for bone, and 67% for soft-tissue metastases, respectively. Notably, brain metastases were initially detected by SSTR-PET in 2 patients, whereas liver and lung metastases were diagnosed exclusively by CT. SSTR-PET showed concordance to CT results in 20 out of 24 patients. Four patients (17%) were up-staged due to SSTR-PET and patient management was changed in 3 patients (13%).


SSTR-PET showed high sensitivity for imaging bone, soft tissue and brain metastases, and particularly in combination with CT had a significant impact on clinical stage and patient management.

Merkel cell carcinoma; Molecular imaging; Somatostatin receptor expression; Positron emission tomography